Risk factors for nosocomial bloodstream infections in COVID-19 affected patients: protocol for a case-control study.
COVID-19
case-control studies
critical care
drug-related side effects and adverse reactions
hospital
pharmacy service
Journal
European journal of hospital pharmacy : science and practice
ISSN: 2047-9956
Titre abrégé: Eur J Hosp Pharm
Pays: England
ID NLM: 101578294
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
03
03
2021
accepted:
05
07
2021
pubmed:
18
8
2021
medline:
11
3
2022
entrez:
17
8
2021
Statut:
ppublish
Résumé
Nosocomial bloodstream infection (nBSI) is an important clinical concern among COVID-19 hospitalised patients. It can cause sepsis and septic shock leading to high morbidity, mortality, and the emergence of antibiotic resistance. The aim of this case-control study is to identify the risk factors associated with the nBSI development in COVID-19 hospitalised patients and its incidence. A retrospective case-control study will be performed. Cases will include nBSI episodes of adult patients (≥18 years) admitted to Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, from April to December 2020 with a diagnosis of SARS-CoV-2 pneumonia. Patients transferred from other hospitals will be excluded. Controls will include hospitalisation episodes of COVID-19 patients without nBSI. We will recruit a minimum of 74 nBSI episodes (cases) and 74 controls (according to sample size calculation). We will collect data on sociodemographics, clinical status at admission, hospital admission, in-hospital mortality, and exposure data (use of antivirals, glucocorticoids or immunomodulatory agents, length of hospitalisation, and use of medical devices such as intravenous catheters). A bivariate and a subsequent multivariate regression analysis will be performed to assess the independent effect of the associated risk factors after adjusting for confounders. The nBSI incidence rate will be estimated according to the number of nBSI episodes in admitted COVID-19 patients among the total person-month of follow-up. The protocol of this study was approved by the Ethical Committee for Drug Investigation of the Hospital Universitari Germans Trias i Pujol. The results of this case-control study will be published in a peer reviewed journal.
Sections du résumé
BACKGROUND
BACKGROUND
Nosocomial bloodstream infection (nBSI) is an important clinical concern among COVID-19 hospitalised patients. It can cause sepsis and septic shock leading to high morbidity, mortality, and the emergence of antibiotic resistance. The aim of this case-control study is to identify the risk factors associated with the nBSI development in COVID-19 hospitalised patients and its incidence.
METHODS AND ANALYSIS
METHODS
A retrospective case-control study will be performed. Cases will include nBSI episodes of adult patients (≥18 years) admitted to Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, from April to December 2020 with a diagnosis of SARS-CoV-2 pneumonia. Patients transferred from other hospitals will be excluded. Controls will include hospitalisation episodes of COVID-19 patients without nBSI. We will recruit a minimum of 74 nBSI episodes (cases) and 74 controls (according to sample size calculation). We will collect data on sociodemographics, clinical status at admission, hospital admission, in-hospital mortality, and exposure data (use of antivirals, glucocorticoids or immunomodulatory agents, length of hospitalisation, and use of medical devices such as intravenous catheters). A bivariate and a subsequent multivariate regression analysis will be performed to assess the independent effect of the associated risk factors after adjusting for confounders. The nBSI incidence rate will be estimated according to the number of nBSI episodes in admitted COVID-19 patients among the total person-month of follow-up.
ETHICS AND DISSEMINATION
BACKGROUND
The protocol of this study was approved by the Ethical Committee for Drug Investigation of the Hospital Universitari Germans Trias i Pujol. The results of this case-control study will be published in a peer reviewed journal.
Identifiants
pubmed: 34400550
pii: ejhpharm-2021-002776
doi: 10.1136/ejhpharm-2021-002776
pmc: PMC8899639
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2-e5Informations de copyright
© European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
N Engl J Med. 2020 Apr 2;382(14):1309-1319
pubmed: 32242356
Crit Care. 2011;15(2):R100
pubmed: 21418635
Risk Manag Healthc Policy. 2020 Nov 13;13:2593-2599
pubmed: 33223859
BMJ. 2007 Oct 20;335(7624):806-8
pubmed: 17947786
J Med Virol. 2021 Jul;93(7):4564-4569
pubmed: 33822390
J Infect. 2018 Jul;77(1):1-8
pubmed: 29746948
Ann Intern Med. 2003 Jul 15;139(2):137-47
pubmed: 12859163
Infection. 2019 Feb;47(1):77-85
pubmed: 30370489
Clin Microbiol Infect. 2021 Feb;27(2):215-227
pubmed: 33161150
Lancet Infect Dis. 2011 Jan;11(1):30-8
pubmed: 21126917
J Infect Public Health. 2019 Jan - Feb;12(1):37-42
pubmed: 30266540
Infect Dis (Lond). 2020 Nov - Dec;52(12):919-922
pubmed: 32779951
Clin Microbiol Infect. 2015 Apr;21(4):313-22
pubmed: 25753137
Am J Infect Control. 2015 Nov;43(11):1222-37
pubmed: 26298636
Eur J Clin Invest. 2020 Oct;50(10):e13319
pubmed: 32535894
Clin Microbiol Infect. 2021 Jan;27(1):47-54
pubmed: 33190794
Jpn J Infect Dis. 2021 Jul 21;74(4):307-315
pubmed: 33390434
Clin Infect Dis. 2020 Dec 17;71(10):2736-2743
pubmed: 32361747
Open Forum Infect Dis. 2020 Sep 30;7(11):ofaa461
pubmed: 33209951
J Infect Prev. 2018 Jan;19(1):37-42
pubmed: 29317913
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
J Am Geriatr Soc. 2014 Feb;62(2):306-11
pubmed: 24438554
Clin Microbiol Infect. 2012 Sep;18(9):E355-61
pubmed: 22784359
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Crit Care Med. 2008 Jul;36(7):2041-7
pubmed: 18552694
Clin Microbiol Infect. 2013 Jun;19(6):501-9
pubmed: 23473333
Intensive Care Med. 2021 Feb;47(2):180-187
pubmed: 33506379
J Med Virol. 2020 Apr;92(4):401-402
pubmed: 31950516
Clin Infect Dis. 2002 Jun 15;34(12):1600-6
pubmed: 12032895
Haematologica. 2014 Jul;99(7):1130-3
pubmed: 24986874
J Infect. 2020 Aug;81(2):266-275
pubmed: 32473235
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
PLoS One. 2020 Nov 23;15(11):e0242533
pubmed: 33226995
Emerg Microbes Infect. 2020 Dec;9(1):1958-1964
pubmed: 32815458
Br Med Bull. 2019 Dec 11;132(1):5-15
pubmed: 31815280
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629
pubmed: 32711058
Crit Care Med. 2021 Jan 1;49(1):e31-e40
pubmed: 33122577
Intensive Care Med. 2012 Dec;38(12):1930-45
pubmed: 23011531
J Glob Antimicrob Resist. 2020 Dec;23:290-291
pubmed: 33130024
Chest. 2011 Apr;139(4):810-815
pubmed: 21106655
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32404482
J Infect Public Health. 2014 May-Jun;7(3):224-32
pubmed: 24631369
Intern Med. 2005 Nov;44(11):1157-62
pubmed: 16357453
Clin Infect Dis. 2006 Apr 15;42(8):1118-26
pubmed: 16575729
Indian Pediatr. 2016 Sep 8;53(9):790-792
pubmed: 27484446
JAMA. 2020 Oct 6;324(13):1292-1295
pubmed: 32876693
Open Forum Infect Dis. 2020 Nov 12;7(11):ofaa518
pubmed: 33269299
Int J Infect Dis. 2018 Jun;71:59-64
pubmed: 29649549
PLoS One. 2019 Dec 10;14(12):e0225765
pubmed: 31821331
Jpn J Infect Dis. 2003 Feb;56(1):1-7
pubmed: 12711818